Technology | November 28, 2011

Fujifilm Demonstrates Synapse 3D Work-In-Progress Software

This year at RSNA 2011, Fujifilm Medical Systems USA Inc. will demonstrate the latest enhancements to its Synapse 3D advanced visualization software to radiologists. The latest addition to the Synapse line up, Synapse 3D 3.0 is an advanced application that is integrated directly into Synapse PACS and Synapse Cardiovascular. The new application will provide time and cost savings and increased workflow benefits while increasing diagnostic performance.

Synapse 3D 3.0 requires FDA 510(k) clearance and is not yet available for sale in the United States.

For more information: www.fujifilmusa.com

Related Content

ResMD’s enterprise image and document viewing solution provides one simple interface for healthcare professionals across the globe to securely access patient imaging. John W. Ayers, Ph.D., is deputy director of informatics in Altman Clinical and Translational Research Institute and a Qualcomm Institute affiliate at University of California, San Diego. Image courtesy of Qualcomm Institute at UC San Diego

News | Radiology Business

Banyan Software Acquires ResolutionMD from Calgary Scientific, Inc.

February 1, 2024 — Banyan Software, a leading acquirer and permanent home for great software businesses, announces the ...

February 01, 2024

New software solution allows hospitals to track 3D printing and planning workflow, ensuring each step is quality-compliant

News | Medical 3-D Printing

Materialise Introduces Mimics Flow Case Management Supporting Quality Management and Compliance for Hospital 3D Printing Labs

December 6, 2023 — Materialise, a global leader in 3D planning and printing services for the medical industry, has ...

December 06, 2023

Videos | Radiation Oncology

VIDEO: 3-D Virtual Reality Aids Patient Understanding of Their Cancer and Therapy

Douglas E. Holt, M.D., a radiation oncologist at Eastern Idaho Regional Medical Center, explains the use of 3-D virtual ...

February 02, 2022

Videos | Computed Tomography (CT)

VIDEO: Photon-counting Detector is a Key CT Advance

Cynthia McCollough, Ph.D., director of Mayo Clinic's CT Clinical Innovation Center, explains how photon-counting ...

January 27, 2022

Cydar EV Maps assists in the planning, real-time guidance, and post-procedure review of endovascular surgery.

News | Mobile C-Arms

Endovascular 3D Image Guidance Added to Philips Zenition Mobile C-arm

January 18, 2022 – Philips Healthcare announced physicians will now have access to advanced new 3D image guidance ...

January 18, 2022

Canon's Vitrea PACS enterprise imaging system was one of several systems demonstrated at HIMSS 2021 that had easily modified hanging protocols. This included ease of use to customize what each radiologists prefers, including slice thickness. #HIMSS #HIMSS21

Feature | Enterprise Imaging

Advances in PACS and Enterprise Imaging Systems at HIMSS 2021

Taking advantage of new technology advances, several radiology PACS, enterprise imaging and cardiovascular information ...

November 04, 2021

The Siemens Naeotom Alpha is the first commercialized photon-counting CT scanner. It gained FDA clearance Sept. 30, 2021. The image shows the system undergoing phantom testing with the outer covers off, showing the motion of the X-ray source and detector ring. Image by Deutscher Zukunftpreis/Ansgar Pudenz.

Feature | Computed Tomography (CT) | By Dave Fornell, ITN Editor

First Photon-counting CT System Cleared by the FDA

The U.S. Food and Drug Administration (FDA) cleared the world's first photon-counting computed tomography (CT) scanner ...

November 04, 2021

$Cardiac CTA derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess TAVR patient risk during pre-procedure workup and post-procedural surveillance. These images show LAVmax (A and B), LAVmin (C and D), and LAEF using cardiac CTA. LAEF was calculated as (LAVmax-LAVmin)/LAVmax x 100. Given LAVmax of 109 mL and LAVmin of 80 mL, the LAEF was calculated to be 27%. Image courtesy of AJR.$